NCE-1 Intelligence & Market Opportunity

Zegalogue

Dasiglucagon

Antihypoglycemic agent

Subcutaneous Solution

Approval Date

22-Mar-21

NCE-1 Date

22-Mar-25

NCE Date

22-Mar-26

Commercial snapshot

Market performance & projections

Revenue ($M)

CAGR (%)

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

2027

127

2028

165

2029

197

2030

223

2031

243

2032

160

Molecule profile

Details & specifications

Molecule

Dasiglucagon

Innovator

NOVO NORDISK

Dosage Form

Subcutaneous Solution

Strength

EQ 0.6 mg base/0.6 mL (EQ 0.6 mg base/0.6 mL)

Therapeutic Category

Antihypoglycemic agent

Usage

To treat severe hypoglycemia

Good to know

Frequently asked questions

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.